<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">cancersp</journal-id><journal-title-group><journal-title xml:lang="ru">Южно-Российский онкологический журнал/ South Russian Journal of Cancer</journal-title><trans-title-group xml:lang="en"><trans-title>South Russian Journal of Cancer</trans-title></trans-title-group></journal-title-group><issn pub-type="epub">2686-9039</issn><publisher><publisher-name>АНО "Перспективы онкологии"</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.37748/2686-9039-2025-6-2-1</article-id><article-id custom-type="edn" pub-id-type="custom">hejatt</article-id><article-id custom-type="elpub" pub-id-type="custom">cancersp-317</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL ARTICLES</subject></subj-group></article-categories><title-group><article-title>Оценка цитотоксического действия 2-(1,1-диметил-1h-бензо[e]индолин-2-ил)-5,6,7-трихлор-1,3-трополона в отношении клеточной линии U87 MG глиобластомы человека</article-title><trans-title-group xml:lang="en"><trans-title>The assessment of the cytotoxic activity of 2-(1,1-dimethyl-1H-benzo[e]indolin-2-yl)-5,6,7-trichloro-1,3-tropolone against the human glioblastoma U87 MG cell line</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3753-4463</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ходакова</surname><given-names>Д. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Khodakova</surname><given-names>D. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ходакова Дарья Владиславовна – младший научный сотрудник испытательного лабораторного центра, ФГБУ «Национальный медицинский исследовательский центр онкологии» Министерства здравоохранения Российской Федерации, г. Ростов-на-Дону, Российская Федерация</p><p>ORCID: <ext-link xlink:href="https://orcid.org/0000-0003-3753-4463" ext-link-type="uri">https://orcid.org/0000-0003-3753-4463</ext-link>, SPIN: 8718-3983, AuthorID: 1056414, ResearcherID: MCK-3167-2025, Scopus Author ID: 57221463056</p></bio><bio xml:lang="en"><p>Darya V. Khodakova – junior researcher at the testing Laboratory Center, National Medical Research Centre for Oncology, Rostov-on-Don, Russian Federation</p><p>ORCID: <ext-link xlink:href="https://orcid.org/0000-0003-3753-4463" ext-link-type="uri">https://orcid.org/0000-0003-3753-4463</ext-link>, SPIN: 8718-3983, AuthorID: 1056414, ResearcherID: MCK-3167-2025, Scopus Author ID: 57221463056</p></bio><email xlink:type="simple">KhodakovaDV@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2337-326X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кузнецова</surname><given-names>Н. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Kuznetsova</surname><given-names>N. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кузнецова Наталья Сергеевна – врач-онколог, ФГБУ «Национальный медицинский исследовательский центр онкологии» Министерства здравоохранения Российской Федерации, г. Ростов-на-Дону, Российская Федерация</p><p>ORCID: <ext-link xlink:href="https://orcid.org/0000-0002-2337-326X" ext-link-type="uri">https://orcid.org/0000-0002-2337-326X</ext-link>, SPIN: 8553-3081, AuthorID: 920734</p></bio><bio xml:lang="en"><p>Natalia S. Kuznetsova – MD, oncologist, National Medical Research Center for Oncology, Rostov-on-Don, Russian Federation</p><p>ORCID: <ext-link xlink:href="https://orcid.org/0000-0002-2337-326X" ext-link-type="uri">https://orcid.org/0000-0002-2337-326X</ext-link>, SPIN: 8553-3081, AuthorID: 920734</p></bio><email xlink:type="simple">kyznet.nat@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4558-5896</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Филиппова</surname><given-names>С. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Filippova</surname><given-names>S. Yu.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Филиппова Светлана Юрьевна – научный сотрудник, лаборатория клеточных технологий, ФГБУ «Национальный медицинский исследовательский центр онкологии» Министерства здравоохранения Российской Федерации, г. Ростов-на-Дону, Российская Федерация</p><p>ORCID: <ext-link xlink:href="https://orcid.org/0000-0002-4558-5896" ext-link-type="uri">https://orcid.org/0000-0002-4558-5896</ext-link>, SPIN: 9586-2785, AuthorID: 878784, ResearcherID: AAH-4408-2020, Scopus Author ID: 5718961884</p></bio><bio xml:lang="en"><p>Svetlana Yu. Filippova – Researcher at the Laboratory of Cellular Technologies, National Medical Research Center for Oncology, Rostov-on-Don, Russian Federation</p><p>ORCID: <ext-link xlink:href="https://orcid.org/0000-0002-4558-5896" ext-link-type="uri">https://orcid.org/0000-0002-4558-5896</ext-link>, SPIN: 9586-2785, AuthorID: 878784, ResearcherID: AAH-4408-2020, Scopus Author ID: 5718961884</p></bio><email xlink:type="simple">filsv@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0676-0871</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Гончарова</surname><given-names>А. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Goncharova</surname><given-names>A. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Гончарова Анна Сергеевна – к.б.н., заведующий испытательного лабораторного центра, ФГБУ «Национальный медицинский исследовательский центр онкологии» Министерства здравоохранения Российской Федерации, г. Ростов-на-Дону, Российская Федерация</p><p>ORCID: <ext-link xlink:href="https://orcid.org/0000-0003-0676-0871" ext-link-type="uri">https://orcid.org/0000-0003-0676-0871</ext-link>, SPIN: 7512-2039, AuthorID: 553424, Scopus Author ID: 57215862139</p></bio><bio xml:lang="en"><p>Anna S. Goncharova – Cand. Sci. (Biol.), head of testing Laboratory Center, National Medical Research Centre for Oncology, Rostov-on-Don, Russian Federation</p><p>ORCID: <ext-link xlink:href="https://orcid.org/0000-0003-0676-0871" ext-link-type="uri">https://orcid.org/0000-0003-0676-0871</ext-link>, SPIN: 7512-2039, AuthorID: 553424, Scopus Author ID: 57215862139</p></bio><email xlink:type="simple">fateyeva_a_s@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7823-3865</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Галина</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Galina</surname><given-names>A. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Галина Анастасия Владимировна – младший научный сотрудник испытательного лабораторного центра, ФГБУ «Национальный медицинский исследовательский центр онкологии» Министерства здравоохранения Российской Федерации, г. Ростов-на-Дону, Российская Федерация</p><p>ORCID: <ext-link xlink:href="https://orcid.org/0000-0001-7823-3865" ext-link-type="uri">https://orcid.org/0000-0001-7823-3865</ext-link>, SPIN: 9171-4476, AuthorID: 1071933, Scopus Author ID: 57221460594</p></bio><bio xml:lang="en"><p>Anastasia V. Galina – junior researcher at the testing Laboratory Center, National Medical Research Centre for Oncology, Rostov-on-Don, Russian Federation</p><p>ORCID: <ext-link xlink:href="https://orcid.org/0000-0001-7823-3865" ext-link-type="uri">https://orcid.org/0000-0001-7823-3865</ext-link>, SPIN: 9171-4476, AuthorID: 1071933, Scopus Author ID: 57221460594</p></bio><email xlink:type="simple">Volkovaav58@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9747-8515</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Гурова</surname><given-names>С. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Gurova</surname><given-names>S. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Гурова Софья Валерьевна – младший научный сотрудник испытательного лабораторного центра, ФГБУ «Национальный медицинский исследовательский центр онкологии» Министерства здравоохранения Российской Федерации, г. Ростов-на-Дону, Российская Федерация</p><p>ORCID: <ext-link xlink:href="https://orcid.org/0000-0002-9747-8515" ext-link-type="uri">https://orcid.org/0000-0002-9747-8515</ext-link>, SPIN: 5413-6901, AuthorID: 1147419</p></bio><bio xml:lang="en"><p>Sofya V. Gurova – junior researcher at the testing Laboratory Center, National Medical Research Centre for Oncology, Rostov-on-Don, Russian Federation</p><p>ORCID: <ext-link xlink:href="https://orcid.org/0000-0002-9747-8515" ext-link-type="uri">https://orcid.org/0000-0002-9747-8515</ext-link>, SPIN: 5413-6901, AuthorID: 1147419</p></bio><email xlink:type="simple">gurova.sophie@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7593-1334</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Гусаков</surname><given-names>Е. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Gusakov</surname><given-names>E. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Гусаков Евгений Александрович – к.х.н., научный сотрудник, Научно-исследовательский институт физической и органической химии ФГАОУ ВПО «Южного федерального университета», г. Ростов-на-Дону, Российская Федерация</p><p>ORCID: <ext-link xlink:href="https://orcid.org/0000-0001-7593-1334" ext-link-type="uri">https://orcid.org/0000-0001-7593-1334</ext-link>, SPIN: 1690-9488, AuthorID: 789745, Scopus Author ID: 55180460600</p></bio><bio xml:lang="en"><p>Evgeniy A. Gusakov – Cand. Sci. (Chem.), Researcher at the Research Institute of Physical and Organic Chemistry, Southern Federal University, Rostov-on-Don, Russian Federation</p><p>ORCID: <ext-link xlink:href="https://orcid.org/0000-0001-7593-1334" ext-link-type="uri">https://orcid.org/0000-0001-7593-1334</ext-link>, SPIN: 1690-9488, AuthorID: 789745, Scopus Author ID: 55180460600</p></bio><email xlink:type="simple">gusakovevgeniy@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3180-1762</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Саяпин</surname><given-names>Ю. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Sayapin</surname><given-names>Yu. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Саяпин Юрий Анатольевич – к.х.н., заведующий лабораторией физической и органической химии, ФГБУН «Федеральный исследовательский центр Южный научный центр Российской академии наук», г. Ростов-на-Дону, Российская Федерация</p><p>ORCID: <ext-link xlink:href="http://orcid.org/0000-0002-3180-1762" ext-link-type="uri">http://orcid.org/0000-0002-3180-1762</ext-link>, SPIN: 4877-3959, AuthorID: 121929</p></bio><bio xml:lang="en"><p>Yurii A. Sayapin – Cand. Sci. (Chem.), Head of the Laboratory of Physical and Organic Chemistry, Federal Research Center at the Southern Scientific Center of the Russian Academy of Sciences, Rostov-on-Don, Russian Federation</p><p>ORCID: <ext-link xlink:href="https://orcid.org/0000-0002-3180-1762" ext-link-type="uri">https://orcid.org/0000-0002-3180-1762</ext-link>, SPIN: 4877-3959, AuthorID: 121929</p></bio><email xlink:type="simple">sayapinscience@gmail.com</email><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2937-0470</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Росторгуев</surname><given-names>Э. Е.</given-names></name><name name-style="western" xml:lang="en"><surname>Rostorguev</surname><given-names>E. E.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Росторгуев Эдуард Евгеньевич – д.м.н., заведующий отделением нейроонкологии, ФГБУ «Национальный медицинский исследовательский центр онкологии» Министерства здравоохранения Российской Федерации, г. Ростов-на-Дону, Российская Федерация</p><p>ORCID: <ext-link xlink:href="https://orcid.org/0000-0003-2937-0470" ext-link-type="uri">https://orcid.org/0000-0003-2937-0470</ext-link>, SPIN: 8487-9157, AuthorID: 794808, Scopus Author ID: 57196005138</p></bio><bio xml:lang="en"><p>Eduard E. Rostorguev – MD, Head of the Department of Neuro-Oncology, National Medical Research Center for Oncology, Rostov-on-Don, Russian Federation</p><p>ORCID: <ext-link xlink:href="https://orcid.org/0000-0003-2937-0470" ext-link-type="uri">https://orcid.org/0000-0003-2937-0470</ext-link>, SPIN: 8487-9157, AuthorID: 794808, Scopus Author ID: 57196005138</p></bio><email xlink:type="simple">rostorguev@icloud.com</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБУ «Национальный медицинский исследовательский центр онкологии» Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>National Medical Research Centre for Oncology</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Научно-исследовательский институт физической и органической химии ФГАОУ ВПО «Южного федерального университета»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>National Medical Research Centre for Oncology</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>ФГБУН «Федеральный исследовательский центр Южный научный центр Российской академии наук»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>National Medical Research Centre for Oncology</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>09</day><month>06</month><year>2025</year></pub-date><volume>6</volume><issue>2</issue><fpage>6</fpage><lpage>13</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Ходакова Д.В., Кузнецова Н.С., Филиппова С.Ю., Гончарова А.С., Галина А.В., Гурова С.В., Гусаков Е.А., Саяпин Ю.А., Росторгуев Э.Е., 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="ru">Ходакова Д.В., Кузнецова Н.С., Филиппова С.Ю., Гончарова А.С., Галина А.В., Гурова С.В., Гусаков Е.А., Саяпин Ю.А., Росторгуев Э.Е.</copyright-holder><copyright-holder xml:lang="en">Khodakova D.V., Kuznetsova N.S., Filippova S.Y., Goncharova A.S., Galina A.V., Gurova S.V., Gusakov E.A., Sayapin Y.A., Rostorguev E.E.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.cancersp.com/jour/article/view/317">https://www.cancersp.com/jour/article/view/317</self-uri><abstract><sec><title>Цель исследования</title><p>Цель исследования. Изучить цитотоксический эффект 2-(1,1-диметил-1h-бензо[e]индолин-2-ил)-5,6,7-трихлор-1,3-трополона (JO-122 (2)) на клеточной линии глиобластомы человека U87 MG.</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы. Исследование цитотоксического эффекта трополона JO-122 (2) было выполнено колориметрическим анализом с применением 3-[4,5-диметилтиазол-2- ил]-2,5-дифенилтетразолия бромида (МТТ-тест) на клеточной линии глиобластомы человека U87 MG. Образцы тестируемого вещества были подготовлены путем последовательных двукратных разведений исходного стокового раствора с концентраций 24 мкМ. В качестве препарата сравнения был использован Темозоломид, его исследуемые дозы находились в диапазоне 250–0.4883 мкМ. Время инкубации после добавления веществ: 24, 48 и 72 ч. Статистическая обработка полученных была проведена в программах Microsoft Excel 2013 и Statistica 10.</p></sec><sec><title>Результаты</title><p>Результаты. В работе был исследован цитотоксический эффект трополона JO-122 (2) на клеточную линию U87 MG. Оценка цитотоксичности показала, что при исследуемых дозах трополона наблюдалось статистически значимое ингибирование роста клеток линии U87. Через 24, 48 и 72 часа необходимая минимальная концентрация JO-122 (2) для подавления роста опухолевых клеток составила 3 мкМ, 0.0469 мкМ и 0.1875 мкМ соответственно.</p><p>Препарат сравнения показал менее выраженное подавление роста опухолевой линии в сравнении с трополоном. Для времени инкубации 24 часа не наблюдалось достоверного снижения жизнеспособности клеток ни в одной из исследуемых концентраций. Минимальная концентрация Темозоломида, необходимая для ингибирования роста клеток культуры U87 MG, была получена через 72 часа и составила 3.9063 мкМ.</p></sec><sec><title>Заключение</title><p>Заключение. В результате проведенного исследования было показано, что оба вещества продемонстрировали зависящую от концентрации токсичность в отношении клеточной линии глиобластомы человека. Однако трополон JO-122 (2) показал более выраженную способность подавлять рост культуры U87 MG.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Purpose of the study</title><p>Purpose of the study. To study the cytotoxic effect of 2-(1,1-dimethyl-1H-benzo[e]indolin-2-yl)-5,6,7-trichloro-1,3-tropolone (JO-122 (2)) on the U87 MG cell line.</p></sec><sec><title>Materials and methods</title><p>Materials and methods. The investigation of the cytotoxic effect of synthesized tropolone JO-122 (2) was performed using the standard MTT colorimetric assay on the human glioblastoma cell line U87 MG. Test substance samples were prepared by sequential twofold dilutions of the original stock solution with concentrations of 24 μM. Temozolomide was used as a reference drug, and its tested doses fell in the range of 250 to 0.4883 μM. Incubation time after the addition of the substances were 24, 48, and 72 hours. The statistical processing of the obtained data was carried out using Microsoft Excel 2013 and Statistica 10 software.</p></sec><sec><title>Results</title><p>Results. The cytotoxic effect of 2-(1,1-dimethyl-1H-benzo[e]indolin-2-yl)-5,6,7-trichloro-1,3-tropolone on the U87 MG cell line was investigated in the study. The assessment of cytotoxicity showed that at all investigated doses of tropolone, there was a statistically significant inhibition of cell growth in the U87 MG cell line. After 24, 48, and 72 hours, the necessary minimum concentration of JO-122 (2) for suppressing tumor cell growth was 3 μM, 0.0469 μM, and 0.1875 μM, respectively.</p><p>The comparison drug showed less pronounced suppression of tumor cell growth compared to tropolone. For an incubation time of 24 hours, no significant decrease in cell viability was observed in any of the tested concentrations. The minimum concentration of Temozolomide required to inhibit U87 MG cell culture growth was obtained after 72 hours and was 3.9063 μM.</p></sec><sec><title>Conclusion</title><p>Conclusion. The conducted research demonstrated that both substances exhibited concentration-dependent toxicity towards the human glioblastoma cell line. However, tropolone JO-122 (2) showed a more pronounced ability to suppress the growth of the U87 MG cell line.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>глиобластома</kwd><kwd>трополон</kwd><kwd>опухолевая культура клеток U87</kwd><kwd>МТТ-тест</kwd><kwd>оценка цитотоксичности</kwd></kwd-group><kwd-group xml:lang="en"><kwd>glioblastoma</kwd><kwd>tropolone</kwd><kwd>U87 glioblastoma cell line</kwd><kwd>MTT assay</kwd><kwd>cytotoxicity assay</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Lukas RV, Wainwright DA, Ladomersky E, Sachdev S, Sonabend AM, Stupp R. Newly Diagnosed Glioblastoma: A Review on Clinical Management. Oncology (Williston Park). 2019 Mar 13;33(3):91–100.</mixed-citation><mixed-citation xml:lang="en">Lukas RV, Wainwright DA, Ladomersky E, Sachdev S, Sonabend AM, Stupp R. Newly diagnosed glioblastoma: A review on clinical management. Oncology (Williston Park). 2019;33:91-100.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Кит О. И., Бандовкина В. А., Франциянц Е. М., Росторгуев Э. Е., Балязин-Парфенов И. В., Черярина Н. Д. Роль гормонального фактора в развитии первичного и вторичного опухолевого процесса в головном мозге. Опухоли головы и шеи. 2016;6(2):50–55. https://doi.org/10.17650/2222-1468-2016-6-2-50-55, EDN: WCNJYJ</mixed-citation><mixed-citation xml:lang="en">Kit OI, Bandovkina VA, Frantsiyants EM, Rostorguev EE, Balyazin-Parfenov IV, Cheryarina ND. Role of hormonal factor in development of primary and secondary tumorous process in the brain. Head and Neck Tumors. 2016;(2):50-55. (In Russ.). https://doi.org/10.17 650 / 2222-1468-2016-6-2-50-54.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Улитин А. Ю., Желудкова О. Г., Иванов П. И., Кобяков Г. Л., Мацко М. В., Насхлеташвили Д. Р. и др. Практические рекомендации по лекарственному лечению первичных опухолей центральной нервной системы. Злокачественные опухоли. 2022;12(3S2-1):113–140. https://doi.org/10.18027/2224-5057-2022-12-3s2-113-140, EDN: NYGIAV</mixed-citation><mixed-citation xml:lang="en">Ulitin AYu, Zheludkova OG, Ivanov PI, Kobyakov GL, Macko MV, Naskhletashvili DR, et al. Practical recommendations for drug treatment of primary tumors of the central nervous system. Malignant tumours. 2022;12(3S2-1):113-140. (In Russ.).  https://doi.org/10.18027/2224-5057-2022-12-3s2-113-140</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Grochans S, Cybulska AM, Simińska D, Korbecki J, Kojder K, Chlubek D, et al. Epidemiology of Glioblastoma Multiforme-Literature Review. Cancers (Basel). 2022 May 13;14(10):2412. https://doi.org/10.3390/cancers14102412</mixed-citation><mixed-citation xml:lang="en">Grochans S, Cybulska AM, Simińska D, Korbecki J, Kojder K, Chlubek D, Baranowska-Bosiacka I. Epidemiology of glioblastoma multiforme–literature review. Cancers. 2022;14(10):2412. https://doi.org/10.3390/cancers14102412.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Liu N, Song W, Schienebeck CM, Zhang M, Tang W. Synthesis of Naturally Occurring Tropones and Tropolones. Tetrahedron. 2014 Dec 9;70(49):9281–9305. https://doi.org/10.1016/j.tet.2014.07.065</mixed-citation><mixed-citation xml:lang="en">Liu N, Song W, Schienebeck CM, Zhang M, Tang W. Synthesis of naturally occurring tropones and tropolones. Tetrahedron. 2014;70(49):9281-9305. https://doi.org/10.1016/j.tet.2014.07.065.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Yang SC, Chen HY, Chuang WL, Wang HC, Hsieh CP, Huang YF. Different Cell Responses to Hinokitiol Treatment Result in Senescence or Apoptosis in Human Osteosarcoma Cell Lines. Int J Mol Sci. 2022 Jan 31;23(3):1632. https://doi.org/10.3390/ijms23031632</mixed-citation><mixed-citation xml:lang="en">Yang SC, Chen HY, Chuang WL, Wang HC, Hsieh CP, Huang YF. Different cell responses to hinokitiol treatment result in senescence or apoptosis in human osteosarcoma cell lines. International Journal of Molecular Sciences. 2020;23(3):1632. https://doi.org/10.3390/ijms23031632.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Haas M, Lenz T, Kadletz-Wanke L, Heiduschka G, Jank BJ. The radiosensitizing effect of β-Thujaplicin, a tropolone derivative inducing S-phase cell cycle arrest, in head and neck squamous cell carcinoma-derived cell lines. Invest New Drugs. 2022 Aug;40(4):700–708. https://doi.org/10.1007/s10637-022-01229-3</mixed-citation><mixed-citation xml:lang="en">Haas M, Lenz T, Kadletz-Wanke L, Heiduschka G, Jank BJ. The radiosensitizing effect of β-Thujaplicin, a tropolone derivative inducing S-phase cell cycle arrest, in head and neck squamous cell carcinoma-derived cell lines. Investigational New Drugs. 2022;40(4):700-708. https://doi.org/10.1007/s10637-022-01229-3.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Ibragimov AA, Enikeeva ZM, Agzamova NA, Salihov FS, Rahimov OA, Askarova MT. Investigation of Mechanism Activity of Antitumor and Radiosensitizing Activity of Preparations К-26 and K-26w. Am J Biomed Life Sci. 2020 Sep;8(5):131–136. https://doi.org/10.11648/j.ajbls.20200805.12</mixed-citation><mixed-citation xml:lang="en">Ibragimov AA, Enikeeva ZM, Agzamova NA, Salihov FS, Rahimov OA, Askarova MT. Investigation of Mechanism Activity of Antitumor and Radiosensitizing Activity of Preparations К-26 and K-26w. American Journal of Biomedical and Life Sciences. 2020;8(5):131-136. doi: 10.11648/j.ajbls.20200805.12.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Патент Российской Федерации RU 2810581 C1. Минкин В. И., Кит О. И., Саяпин Ю. А., Максимов А. Ю., Гончарова А. С., Гусаков Е. А. и др. 2-(1,1-Диметил-1H-бензо[e]индолин-2-ил)-5,6,7-трихлор-1,3-трополон, обладающий цитотоксической активностью по отношению к культуре клеток рака кожи А431 и рака легкого Н1299. Заявлено 08.11.2023. Опубликовано 27.12.2023.</mixed-citation><mixed-citation xml:lang="en">Minkin VI, Kit OI, Sayapin YuA, Maksimov A Yu, Goncharova AS, Gusakov EA, et al. 2-(1,1-Dimethyl-1H-benzo[e]indolin-2-yl)-5,6,7-trichloro-1,3-tropolone, which has cytotoxic activity against A431 skin cancer and H1299 lung cancer cell cultures. Patent Russian Federation RU 2810581 C1. 2023 December 27.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Ma QG, Wei RR, Zhang XD, Sang ZP, Dong JH, Lu QX, et al. Tropolone derivatives with hepatoprotective and antiproliferative activities from the aerial parts of Chenopodium album Linn. Fitoterapia. 2020 Oct;146:104733. https://doi.org/10.1016/j.fitote.2020.104733</mixed-citation><mixed-citation xml:lang="en">Ma QG, Wei RR, Zhang XD, Sang ZP, Dong JH, Lu QX, et al. Tropolone derivatives with hepatoprotective and antiproliferative activities from the aerial parts of Chenopodium album Linn. Fitoterapia.2020;146:104733. https://doi.org/10.1016/j.fitote.2020.104733.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Balsa LM, Ruiz MC, Santa Maria de la Parra L, Baran EJ, León IE. Anticancer and antimetastatic activity of copper(II)-tropolone complex against human breast cancer cells, breast multicellular spheroids and mammospheres. J Inorg Biochem. 2020 Mar;204:110975. https://doi.org/10.1016/j.jinorgbio.2019.110975</mixed-citation><mixed-citation xml:lang="en">Balsa LM, Ruiz MC, de la Parra LSM, Baran EJ, León IE. Anticancer and antimetastatic activity of copper (II)-tropolone complex against human breast cancer cells, breast multicellular spheroids and mammospheres. Journal of Inorganic Biochemistry. 2020;204:110975. https://doi.org/10.1016/j.jinorgbio.2019.110975.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Haney SL, Feng D, Kollala SS, Chhonker YS, Varney ML, Williams JT, et al. Investigation of the activity of a novel tropolone in osteosarcoma. Drug Dev Res. 2024 Feb;85(1):e22129. https://doi.org/10.1002/ddr.22129</mixed-citation><mixed-citation xml:lang="en">Haney SL, Feng D, Kollala SS, Chhonker YS, Varney ML, Williams JT, et al. Investigation of the activity of a novel tropolone in osteosarcoma. Drug Development Research. 2024;85(1):e22129. https://doi.org/10.1002/ddr.22129.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
